Phospho-Met Base Kit

Click image to enlarge

This kit provides basic components for the quantitative determination of phospho-Met (Tyr1349) in human whole cell lysates. Base kits generally include only MSD plates coated with the capture antibody, SULFO-TAG-labeled antibody, and MSD proprietary read buffer. (See product insert for a list of kit components). Base kits are most commonly used for high-throughput screening and assay development.

Specifications
Documentation
References

Application(s)		Phosphoproteins , Intracellular Signaling
Analyte(s)		Met
Species		Human
Instrument(s)		SECTOR Imager 2400 , SECTOR Imager 6000 , MESO QuickPlex SQ 120 , MESO QuickPlex SQ 120MM , MESO SECTOR S 600 , MESO SECTOR S 600MM
Plate Type		96-well
Capture Antibody		Rabbit Polyclonal
Detection Antibody		Goat Polyclonal
Usage Statement		For Research Use Only. Not for use in diagnostic procedures.
Kit Model		Base
Storage Statement(s)		Please refer to the product insert for the storage conditions of individual kit components.
Storage Condition		2-8 °C

Contact Information

Customer Service/Orders
1-240-314-2795

5:00 a.m. to 8:00 p.m.
US Eastern Time

Email

Scientific/Technical Support
1-240-314-2798

5:30 a.m. to 5:30 p.m.
US Eastern Time

Email

Instrument Support
1-301-947-2057

8:30 a.m. - 5:30 p.m.
US Eastern Time

Email

Company Headquarters
1-240-314-2600
1601 Research Blvd.
Rockville, Maryland 20850-3173
USA

Product Inserts		Phospho Met Tyr1349 Base
Datasheets		DS Phospho Met Tyr1349
SDS		Read Buffer T (4x), Read Buffer S (4x) and Read Buffer S (1x)

Title	Journal	Year
Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET. Wu W, Bi C, Credille KM, Manro JR, Peek VL, Donoho GP, Yan L, Wijsman JA, Yan SB, Walgren RA.	Clin Cancer Res.	2013
Phase II study evaluating 2 dosing schedules of oral Foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. Shah MA, Wainberg ZA, Catenacci DVT, Hochster HS, Ford J, Kunz P, Lee F, Kallender H, Cecchi F, Rabe DC, Keer H, Martin A, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP.	PLoS One	2013
S49076 is a novel kinase inhibitor of MET, AXL and FGFR with strong preclinical activity alone and in association with bevacizumab. Burbridge MF, Bossard CJ, Saunier C, Fejes I, Bruno A, Leonce S, Ferry G, Da Violante G, Bouzom F, Cattan V, Jacquet-Bescond A, Comoglio PM, Lockhart BP, Boutin JA, Cordi A, Ortuno JC, Pierre A, Hickman JA, Cruzalegui FH, Depil S.	Mol Cancer Ther.	2013
Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody Onartuzumab. Jagoda EM, Lang L, Bhadrasetty V, Histed S, Williams M, Kramer-Marek G, Mena E, Rosenblum L, Marik J, Tinianow JN, Merchant M, Szajek L, Paik C, Cecchi F, Raffensperger K, Jose-Dizon JM, Bottaro DP, Choyke P.	J Nucl Med.	2012
Targeted MET inhibition in castration-resistant prostate cancer: A randomized phase 2 study and biomarker analysis with Rilotumumab plus Mitoxantrone and Prednisone. Ryan CJ, Rosenthal M, Ng S, Alumkal J, Picus J, Gravis G, Fizazi K, Forget F, Machiels JP, Srinivas S, Zhu M, Tang R, Oliner KS, Jiang Y, Loh E, Dubey S, Gerritsen WR.	Clin Cancer Res.	2012
View All

Please Sign In

User name

Password

Phospho-Met Base Kit

Top Products

Contact Information

Products

Services

Orders & Support

Key Topics